177 related articles for article (PubMed ID: 21750397)
1. Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a long-acting form of parathyroid hormone.
Ponnapakkam T; Katikaneni R; Nichols T; Tobin G; Sakon J; Matsushita O; Gensure RC
J Endocrinol Invest; 2011 Dec; 34(11):e392-7. PubMed ID: 21750397
[TBL] [Abstract][Full Text] [Related]
2. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice.
Ponnapakkam T; Katikaneni R; Miller E; Ponnapakkam A; Hirofumi S; Miyata S; Suva LJ; Sakon J; Matsushita O; Gensure RC
Calcif Tissue Int; 2011 Jun; 88(6):511-20. PubMed ID: 21512758
[TBL] [Abstract][Full Text] [Related]
3. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice.
Ponnapakkam T; Katikaneni R; Suda H; Miyata S; Matsushita O; Sakon J; Gensure RC
Calcif Tissue Int; 2012 Sep; 91(3):196-203. PubMed ID: 22806683
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
[TBL] [Abstract][Full Text] [Related]
5. Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain.
Katikaneni R; Ponnapakkam T; Suda H; Miyata S; Sakon J; Matsushita O; Gensure RC
Int J Cancer; 2012 Sep; 131(5):E813-21. PubMed ID: 22130912
[TBL] [Abstract][Full Text] [Related]
6. Treatment and prevention of chemotherapy-induced alopecia with PTH-CBD, a collagen-targeted parathyroid hormone analog, in a non-depilated mouse model.
Katikaneni R; Ponnapakkam T; Matsushita O; Sakon J; Gensure R
Anticancer Drugs; 2014 Jan; 25(1):30-8. PubMed ID: 24025564
[TBL] [Abstract][Full Text] [Related]
7. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.
Horwitz MJ; Tedesco MB; Gundberg C; Garcia-Ocana A; Stewart AF
J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182
[TBL] [Abstract][Full Text] [Related]
8. Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
Shen L; Xie X; Su Y; Luo C; Zhang C; Zeng B
PLoS One; 2011; 6(10):e26267. PubMed ID: 22022584
[TBL] [Abstract][Full Text] [Related]
9. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
10. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G
Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
[TBL] [Abstract][Full Text] [Related]
11. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial.
Finkelstein JS; Klibanski A; Arnold AL; Toth TL; Hornstein MD; Neer RM
JAMA; 1998 Sep 23-30; 280(12):1067-73. PubMed ID: 9757854
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
[TBL] [Abstract][Full Text] [Related]
13. Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.
Vestergaard P; Jorgensen NR; Mosekilde L; Schwarz P
Osteoporos Int; 2007 Jan; 18(1):45-57. PubMed ID: 16951908
[TBL] [Abstract][Full Text] [Related]
14. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate.
Rittmaster RS; Bolognese M; Ettinger MP; Hanley DA; Hodsman AB; Kendler DL; Rosen CJ
J Clin Endocrinol Metab; 2000 Jun; 85(6):2129-34. PubMed ID: 10852440
[TBL] [Abstract][Full Text] [Related]
16. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
[TBL] [Abstract][Full Text] [Related]
17. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
18. Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.
Fogelman I; Fordham JN; Fraser WD; Spector TD; Christiansen C; Morris SA; Fox J
Calcif Tissue Int; 2008 Aug; 83(2):85-92. PubMed ID: 18626566
[TBL] [Abstract][Full Text] [Related]
19. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
Black DM; Bilezikian JP; Greenspan SL; Wüster C; Muñoz-Torres M; Bone HG; Rosen CJ; Andersen HS; Hanley DA
Osteoporos Int; 2013 Apr; 24(4):1503-11. PubMed ID: 22930240
[TBL] [Abstract][Full Text] [Related]
20. Mineral bone disorder and osteoporosis in hemodialysis patients.
Slouma M; Sahli H; Bahlous A; Laadhar L; Smaoui W; Rekik S; Gharsallah I; Sallami M; Moussa FB; Elleuch M; Cheour E
Adv Rheumatol; 2020 Feb; 60(1):15. PubMed ID: 32102689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]